News
Instil Bio
TIL · NASDAQ
$5.94+$0.15 (+2.59%)TodayMarket closed ·
Prev close $5.79
Latest news
- News
Earnings Scheduled For March 27, 2026
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
- NewsAvi Kapoor
Dow Jumps Over 400 Points; US Services Activity Falls In December
- NewsVandana Singh
Instil Bio Pulls Plug On Lead Drug Development
- NewsAvi Kapoor
US Stocks Mixed; Nasdaq Gains Over 50 Points
- Press releaseGlobe Newswire
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
- Press releaseGlobe Newswire
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
- Press releaseGlobe Newswire
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
Instil Bio, ImmuneOnco Advance Lung Cancer Drug '2510 With New Trials in China and US Plans Ahead
- Press releaseGlobe Newswire
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ('2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
- NewsAvi Kapoor
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
- NewsAvi Kapoor
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.